Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Rigel Pharmaceuticals Inc changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 162 | 1 | 163 | +2 |
| Shares | 138.1M | 165 | 135.4M | −2.71M (−2.0%) |
| Value | $365.9M | $0 | $405.7M | +$39.8M (+10.9%) |
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 823,664 | $2.46M | 0.04% |
| Assenagon Asset Management S.A. | 753,110 | $2.25M | 0.01% |
| Algert Global LLC | 143,592 | $429.0K | 0.03% |
| Connecticut Wealth Management, LLC | 80,000 | $239.0K | 0.02% |
| Engineers Gate Manager LP | 34,519 | $103.0K | 0.00% |
| Amalgamated Financial Corp. | 27,816 | $83.0K | 0.00% |
| Sciencast Management LP | 15,681 | $49.0K | 0.01% |
| Balyasny Asset Management LLC | 15,487 | $46.0K | 0.00% |
| Corient Capital Partners, LLC | 13,262 | $40.0K | 0.00% |
| Quadrant Capital Group LLC | 6,263 | $19.0K | 0.00% |
| EverSource Wealth Advisors, LLC | 3,869 | $11.0K | 0.00% |
| Ten Capital Wealth Advisors, LLC | 2,000 | $6.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 1,690 | $5.00K | 0.00% |
| Worth Asset Management, LLC | 1,000 | $2.00K | 0.00% |
| Signaturefd, LLC | 353 | $1.00K | 0.00% |
| Lindbrook Capital, LLC | 374 | $1.00K | 0.00% |
| CWM, LLC | 65 | $0 | 0.00% |
| TCWP LLC | 212 | $0 | 0.00% |
Sold out (16)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| HealthInvest Partners AB | 1,090,000 | $2.89M |
| Sio Capital Management, LLC | 913,621 | $2.42M |
| Artal Group S.A. | 321,100 | $851.0K |
| Sender Co & Partners, Inc. | 195,457 | $518.0K |
| HAP Trading, LLC | 99,955 | $265.0K |
| Prelude Capital Management, LLC | 68,900 | $183.0K |
| Caption Management, LLC | 37,900 | $99.0K |
| SG Americas Securities, LLC | 29,307 | $78.0K |
| Shay Capital LLC | 28,128 | $75.0K |
| Manteio Capital LLC | 17,589 | $47.0K |
| Royce & Associates LP | 14,118 | $37.0K |
| Aquatic Capital Management LLC | 13,200 | $35.0K |
| Jupiter Asset Management Ltd | 11,621 | $31.0K |
| Visionary Wealth Advisors | 10,916 | $29.0K |
| Eaton Vance Management | 601 | $2.00K |
| Cornerstone Advisory, LLC | 50 | $0 |
Not filed for Q1 2022 yet (1)
Institutions that held Rigel Pharmaceuticals Inc at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Carroll Financial Associates, Inc. | 165 | $0 |